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mPGES-1(microsomalprostaglandinEsynthase-1)isastimulus-
inducible enzyme that functions downstream of COX (cyclo-
oxygenase)-2 in the PGE2 (prostaglandin E2)-biosynthesis
pathway. Although COX-2-derived PGE2 is known to play a
role in the development of various tumours, the involvement of
mPGES-1 in carcinogenesis has not yet been fully understood.
In the present study, we used LLC (Lewis lung carcinoma)
cells with mPGES-1 knockdown or overexpression, as well as
mPGES-1-deﬁcient mice to examine the roles of cancer cell-
and host-associated mPGES-1 in the processes of tumorigenesis
in vitro and in vivo. We found that siRNA (small interfering
RNA) silencing of mPGES-1 in LLC cells decreased PGE2
synthesis markedly, accompanied by reduced cell proliferation,
attenuated Matrigel
TM invasiveness and increased extracellular
matrix adhesion. Conversely, mPGES-1-overexpressing LLC
cells showed increased proliferating and invasive capacities.
When implanted subcutaneously into wild-type mice, mPGES-1-
silenced cells formed smaller xenograft tumours than did control
cells. Furthermore, LLC tumours grafted subcutaneously into
mPGES-1-knockoutmicegrewmoreslowlythandidthosegrafted
into littermate wild-type mice, with concomitant decreases in
the density of microvascular networks, the expression of pro-
angiogenic vascular endothelial growth factor, and the activity
of matrix metalloproteinase-2. Lung metastasis of intravenously
injected LLC cells was also signiﬁcantly less obvious in mPGES-
1-null mice than in wild-type mice. Thus our present approaches
provide unequivocal evidence for critical roles of the mPGES-1-
dependent PGE2 biosynthetic pathway in both cancer cells and
host microenvironments in tumour growth and metastasis.
Key words: knockout mouse, metastasis, microsomal
prostaglandin E synthase-1, prostaglandin E2, tumorigenesis.
INTRODUCTION
Numerous studies on rodent cancer models and human cancers
have shown that NSAIDs (non-steroidal anti-inﬂammatory
drugs) have antineoplastic properties [1]. A well-known effect
of the NSAIDs is their ability to inhibit the enzyme COX (cyclo-
oxygenase)andtherebytosuppressPG(prostaglandin)synthesis.
PGE2, the most common PG, is involved in tumour progression
byinducingangiogenesis,invasionandmetastasisinseveralsolid
tumours [2]. Biosynthesis of PGE2 from arachidonic acid, which
is spatiotemporally supplied from membrane phospholipids by
the action of phospholipase A2, is catalysed sequentially by COX
and PGES (PGE synthase) [3]. COX catalyses the insertion of
molecular oxygen into arachidonic acid to form the unstable
intermediate PGG2, which is rapidly converted into PGH2 by
the peroxidase activity of the same enzyme. Of the two COX
isoforms, COX-1 is expressed constitutively in most tissues and
is generally responsible for the production of PGs that control
normal physiological functions, whereas COX-2 is inducible
in response to mitogens, cytokines and cellular transformation.
High levels of constitutive expression of COX-2 and its product
PGE2 have been detected in various cancer cells and tissues.
Moreover, pharmacological, cell biological and gene targeting
studies investigating COX-2 and EPs (PGE receptors) have
demonstrated that PGE2 produced through the COX-2-dependent
pathway contributes to the progression of several types of cancer
[4,5].
PGES catalyses the conversion of PGH2, produced by COX-1
or COX-2, into PGE2. Thus far, three PGES enzymes, mPGES
(microsomal PGES)-1, mPGES-2 and cPGES (cytosolic PGES),
have been identiﬁed [6–9]. Among these PGES isozymes,
mPGES-1 is induced by pro-inﬂammatory stimuli and down-
regulated by anti-inﬂammatory glucocorticoids, as in the case
of COX-2, and is functionally coupled with COX-2 in marked
preferencetoCOX-1[7,10,11].InductionofmPGES-1expression
and its function have been observed in various diseases and
systems in which COX-2-driven PGE2 has been implicated,
such as rheumatoid arthritis, febrile response, reproduction, bone
metabolism, cardiovascular function, stroke and Alzheimer’s
disease [12,13]. Furthermore, it has previously been reported
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that mPGES-1 is constitutively expressed in several cancers,
most of which also express COX-2 constitutively [14,15]. We
have reported that the forcible transfection of mPGES-1 in
combination with COX-2, but not with COX-1, into HEK (human
embryonic kidney)-293 cells led to cellular transformation with
a concomitant and robust increase in PGE2 [14]. Transgenic
mice overexpressing both COX-2 and mPGES-1 developed
metaplasia, hyperplasia and tumorous growth in the glandular
stomach with heavy macrophage inﬁltration [16,17]. It has also
been suggested that the PGE2 produced through the COX-2-
dependent pathway may regulate cancer–host communications
that inﬂuence tumour progression. Studies using mice null for
COX-2 or EPs have revealed that stromal cells around cancer
cells express COX-2 and synthesize PGE2, which, in tumour
niches, may act on stromal cells in an autocrine fashion to
induce the production of pro-angiogenic factors and consequent
angiogenesis, as well as on cancer cells in a paracrine fashion
to promote their growth, survival, adhesion and motility [5,18–
20]. Although several studies, including our own, have found,
by immunohistochemistry, that mPGES-1 is expressed in both
stromal cells and cancer cells in tumour tissues [14,21], the
contribution of mPGES-1 expressed in either cell population to
tumour progression has not yet been fully elucidated.
Although the inhibition of COX-2-mediated PGE2 formation
represents a promising chemopreventive strategy for reducing the
risk of cancer, the cardiovascular side effects associated with
COX-2 inhibitors, which most likely result from the blunting
of anti-thrombotic prostacyclin (PGI2), have previously been
found to limit their use [22,23]. From this viewpoint, selective
blockage of the biosynthesis of PGE2 without affecting other
prostanoids appears to be feasible for cancer chemoprevention
with the potential for improved tolerability over NSAIDs. To
better evaluate the efﬁcacy of mPGES-1 inhibition in relieving
symptoms of cancer, the present study used lung carcinoma
cells with mPGES-1 KD (knockdown) or overexpression, as
well as mice null for mPGES-1. Our results provide evidence
that mPGES-1 in both cancer cells and hosts contributes to
tumorigenesis in vitro and in vivo.
EXPERIMENTAL
Cells
LLC(Lewislungcarcinoma)cells,whichwereoriginallyisolated
from C57BL/6 mice, were cultured in DMEM (Dulbecco’s
modiﬁed Eagle’s medium) containing 10% (v/v) FCS (fetal
calf serum) under a humidiﬁed atmosphere containing 5%
CO2. To establish mPGES-1-KD and -overexpressing LLC
cells, we transfected these cells with a pRNA-U6.1/Hygro
siRNA (small interfering RNA) expression vector (GenScript)
harboring an mPGES-1-directed siRNA target sequence [5
 -
GGCCTTTGCCAACCCCGAG-3
  (residues 126–144 in the
open reading frame)] and a pcDNA3.1 expression vector
(Invitrogen) containing mouse mPGES-1 cDNA respectively,
using Lipofectamine
TM 2000 (Invitrogen). After the transfection
of these plasmids, LLC cells were cultured in medium containing
1 mg/mlG418(Invitrogen)toestablishstableclones.Asacontrol,
LLC cells transfected with an empty vector (pRNA-U6.1/Hygro
or pcDNA3.1) were used (referred to as mock cells hereafter).
Animals
C57BL/6 and BALB/c mice were obtained from the Saitama
Animal Center. mPGES-1-KO (knockout) mice were established
as described previously [12,13], and backcrossed at least three
generations with C57BL/6 mice or ten generations with BALB/c
mice. Female mPGES-1-KO mice and littermate WT (wild-
type)mice(7-weeks-old)wereusedineachexperiment.Themice
were housed in microisolator cages in a pathogen-free barrier
facility, and all procedures involving animals were performed in
accordance with protocols approved by the Institutional Animal
Care and Use Committee of Showa University, in accordance
with the Standards Relating to the Care and Management of
Experimental Animals in Japan.
Cell growth assay
Cells were seeded at 6×10
4 cells/well in six-well plates or
1.5×10
5 cells/ﬂask in T-25 culture ﬂasks in culture medium in
the presence or absence of 10 nM NS-398 (Cayman Chemicals),
a COX-2 selective inhibitor, or 1 mM dmPGE2 (16,16-dimethyl
PGE2) (Cayman Chemicals), a metabolically stable analogue
of PGE2. After culture for 72 h, the cells were collected by
trypsinization and counted in a Bright-line haemocytometer in
the presence of Trypan Blue.
Western blot analysis
Aliquotsofsamples(20 μgofproteinequivalents)weresubjected
to SDS/PAGE using 10% (w/v) gels under reducing conditions.
The separated proteins were electroblotted on to nitrocellulose
membranes (Schleicher & Schuell) with a semi-dry blotter (Bio-
Rad). After blocking with 3% (w/v) dried non-fat skimmed
milk in TBS (Tris-buffered saline) (pH 7.4) containing 0.05%
Tween 20 (TBS-Tween), the membranes were probed with the
respective antibodies for 2 h {1:2000 dilution for antibodies
against mPGES-1 [14], mPGES-2 (Cayman Chemicals), cPGES
[11], COX-1 and -2 (Santa Cruz Biotechnology), EP1, 2, 3
and 4 (Cayman Chemicals), and VEGF (vascular endothelial
growth factor; Sigma); and 1:2500 dilution for anti-mouse α-
tubulin antibody (Zymed Laboratories) in TBS-Tween}. After
washing with TBS-Tween, the membranes were incubated with
horseradish peroxidase-conjugated anti-goat (for COX-1, COX-
2 and VEGF), anti-rabbit (for mPGES-1, mPGES-2, cPGES
and EP1–4) and anti-mouse (for α-tubulin) IgG antibodies
(1:5000 dilution in TBS-Tween) for 1 h, and visualized with
the ECL (enhanced chemiluminescence) Western blot system
(PerkinElmer Life Sciences), as described previously [7,13,14].
Amounts of individual proteins relative to that of α-tubulin were
estimated from their signal intensities on the Western blots using
Lane and Spot Analyzer (ATTO).
Determination of PG levels
ForthemeasurementofPGsintissues,mousetissueswerewashed
twice with Hank’s balanced salt solution containing 10 μM
indomethacin (Sigma) before homogenization. The supernatants
obtained from the tissue homogenates were adjusted to pH 3.0
with 1 M HCl and passed through a Sep-Pak C18 cartridge
(Waters),andtheretainedPGswereelutedwith8 mlofmethanol,
as described previously [13]. A trace amount of [
3H]PGE2
(Cayman Chemicals) was added to the samples before passage
through the cartridges to calibrate the recovery of the PGs. The
samplesolventswereevaporated,andthenthePGsweredissolved
in an aliquot of buffer and assayed with commercial enzyme
immunoassay kits for individual PGs (Cayman Chemicals).
Likewise, aliquots of the supernatants of cultured cells were
subjected to the enzyme immunoassay for PGs.
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Adhesion assay
Cells were plated at 2×10
5 cells in 35-mm dishes, which
were pre-treated with collagen, ﬁbronectin or laminin (BD
Biosciences). After incubation for 60 min at 37◦C, the cells were
ﬁxed with Carnoy solution and then stained with Giemsa solution
for 60 min. Adherent cells were counted in three ﬁelds at ×40
magniﬁcation using a microscope and J image software.
Invasion assay
Cell invasiveness was evaluated using a BD BioCoat
TM
Matrigel
TM Invasion Chamber (BD Biosciences) according to
the manufacturer’s instructions. In brief, cells (1.2×10
6 cells in
0.5 ml) suspended in DMEM containing 3% (v/v) FCS and 1%
(v/v) sodium pyruvate (Invitrogen) were seeded on the top of the
gelineachchamber.DMEMcontaining10%(v/v)FCS(0.75 ml)
wasaddedasasourceofchemoattractantsintothebottomwellsof
the plate. After 16 h of incubation, cells that had invaded on to the
lower surface of the chamber were ﬁxed with methanol for 5 min,
and stained with Crystal Violet. Non-invasive cells on the upper
surface were removed with a cotton bud, and the membrane was
cut.Thenumberofinvadingcellswasquantiﬁedbycountingthem
under a light microscope. Statistical signiﬁcance was determined
using the Student’s t test.
Tumour implantation model
LLC cells (1×10
6) in 100 μl of PBS were injected
subcutaneouslyinto8-week-oldfemalemice.Tumourgrowthwas
assessed by the measurement of two bisecting diameters in each
tumour using calipers. The size of the tumour was determined
by direct measurement of the tumour dimensions. The volume
was calculated according to the equation: V =(L×W
2)×0.5,
where V =volume, L=length and W =width [35]. On day
14 after tumour implantation, the mice were anaesthetized and
killed by dislocation of the cervical spine, and the tumour
tissues were dissected, weighed and then ﬁxed in 10% (v/v)
formalin for histochemical analyses. The intratumoral blood
vessels in the most intensive neovascularization areas were
quantiﬁed by staining of the sections with haematoxylin and
eosin followed by silver. For each tumour, ﬁve random images
were captured at ×400 magniﬁcation. Only areas of viable
tumour tissue were imaged; necrotic regions were excluded. The
individual microvessels were counted. The structure of individual
microvesselswasclearlydifferentiatedfromtumourcellsonsilver
staining.Theﬁnalvasculardensityscoreforthetumourrepresents
an average of all scored ﬁelds.
Lung metastasis model
LLC cells (1×10
6) in 100 μl of PBS were intravenously injected
intothelateraltailveinsof8-week-oldfemalemice.Then,14 days
later, the mice were anaesthetized and killed, and the lungs were
removed and weighed. Finally, the lungs were placed in Bouin’s
solution for 24 h and then photographed.
Determination of haemoglobin levels in tumour tissues
The dissected tumour tissues were washed, cut into small pieces
with scissors, and homogenized with a Polytron homogenizer
in a SET buffer [250 mM sucrose, 0.5 mM EDTA and 20 mM
Tris/HCl(pH 7.4)]containing10 μMindomethacin,1 mMPMSF
and 0.5% Triton X-100. The tissue homogenates obtained were
centrifuged at 600 g for 5 min, and an aliquot (200 μl) of the
supernatant was centrifuged again at 14000 g for 30 min at 4◦C.
Concentrations of haemoglobin in the supernatant were then
determined spectrophotometrically by measuring the absorbance
at 540 nm using a haemoglobin assay kit (Wako).
RT (reverse transcriptase)–PCR
Total RNA was isolated from cells and tissues using TRIzol®
(Invitrogen). Synthesis of cDNA was performed with 2 μgo f
the total RNA and avian myeloblastosis virus RT according
to the manufacturer’s instructions supplied with the RNA PCR kit
version 2.1 (Takara Biomedicals). Subsequent ampliﬁcations of
the partial cDNA fragments were performed using 0.5 μl
of the reverse-transcribed mixture as a template with a set of
speciﬁc oligonucleotide primers (Sigma) as follows: (i)
mouse VEGF, sense 5
 -GATGAAGCCCTGGAGTGC-3
  and
antisense 5
 -TCCCAGAAACAACCCTAA-3
 ; and (ii) mouse
GAPDH (glyceraldehyde-3-phosphate dehydrogenase), sense
5
 -TCGTGGATCTGACGTGCCGCCTG-3
  and antisense 5
 -
CACCACCCTBTTGCTGTAGCCGTAT-3
 . The PCR mixtures
were subjected to 30 cycles of ampliﬁcation by denaturation
(30 s at 94◦C), annealing (30 s at 57◦C) and elongation (30 s
at 72◦C). The PCR products were analysed by 1% (w/v) agarose
gel electrophoresis with ethidium bromide.
Real-time RT–PCR
Single-stranded cDNA was generated using 1 μgo ft o t a lR N A
as a template and avian myeloblastosis virus RT, using a high
capacity reverse transcriptase kit (Applied Biosystems). Real-
time PCR was carried out using the SYBR Green PCR Master
Mix (Applied Biosystems) and StepOne (Applied Biosystems)
accordingtothemanufacturer’sinstructions.ThePCRprimersets
used were: (i) mouse EP2, sense 5
 -GCTGTGCTCGCCTGCAA-
3
  and antisense 5
 -CGACGGTGCATGCGAAT-3
 ; (ii) mouse
EP4, sense 5
 -CATCATCTGTGCCATGAGCAT-3
  and antisense
5
 -GCTGTAGAAGTAGGCGTGGTTGA-3
 ; (iii) mouse VEGF,
sense 5
 -TACCTCCACCATGCCAAGTG-3
  and antisense 5
 -
TGGGACTTCTGCTCTCCTTCTG-3
 ; (iv) mouse MMP (matrix
metalloproteinase)-2, sense 5
 -GGACCCCGGTTTCCCTAA-
3
  and antisense 5
 -CAGGTTATCAGGGATGGCATTC-3
 ;( v )
mouse MMP-9, sense 5
 -AGTGGGACCATCATAACATCACAT-
3
  and antisense 5
 -TCTCGCGGCAAGTCTTCAG-3
 ;( v i )
mouse α5 integrin, sense 5
 -ATGGCTCAGACATCCACTCC-
3
  and antisense 5
 -GGTCATCTAGCCCATCTCCA-3
 ; and (vii)
mouse β1 integrin, sense 5
 -GGTGTCGTGTTTGTGAATGC-
3
  and antisense 5
 -TGACGCTAGACATGGACCAG-3
 .T h e
expression levels of EP2, EP4, MMP-2, MMP-9 and
integrins were normalized with those of mouse GAPDH
with a primer set of 5
 -ATGTGTCCGTCGTGGATCTGA-3
 
and 5
 -ATGCCTGCTTCACCACCTTCT-3
 . Results represent an
average of several independent experiments.
Gelatin zymography
Lysates of cells and tissues (27 μg of protein equivalents)
were subjected to SDS/PAGE (10% gels), with 1 mg/ml
gelatin substrate being incorporated into the gels. Following
electrophoresis, the gels were soaked in 2.5% Triton X-100
to remove SDS, rinsed with 10 mM Tris/HCl (pH 8.0), and
transferred to a bath containing 50 mM Tris/HCl(pH 8.0), 5 mM
CaCl2 and 1 μMZ n C l 2 at 37◦C for 18 h. The gels were then
stained with 0.1% C o o m a s s i eB l u ei n4 5% methanol and 10%
acetic acid.
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Figure 1 PGE2 production and cell proliferation in mPGES-1-silenced LLC cells in vitro
(A) Expression of PGE2 biosynthetic enzymes and PGE receptors in mPGES-1-KD and control (mock) cells was assessed by immunoblotting (left-hand panel). Equal amounts of cell lysates (20μg
of protein equivalents) were separated by SDS/PAGE and analysed by Western blotting at the same time with the corresponding antibodies to allow for a direct comparison. Representative results of
at least three experiments are shown. Expression levels of EP2 and EP4 mRNAs in KD and mock cells were evaluated by quantitative RT–PCR, with GAPDH mRNA used for normalization (right-hand
panel). (B–D) Effects of mPGES-1 silencing and 10nM NS-398, a COX-2 selective inhibitor, on production of PGE2 (B), 6-keto PGF1α and PGF2α (C), and on cell proliferation (D). mPGES-1-KD
and mock cells were seeded at 6×104 cells/well in six-well culture dishes in the presence or absence of 10nM NS-398. After culture for 3 days, the cells were collected and counted in a Bright-line
haemocytometer in the presence of Trypan Blue, and the supernatants were taken for enzyme immunoassay of several PGs. (E) Effect of dmPGE2 on cell proliferation. mPGES-1-KD and mock cells
were seeded in T-25 culture ﬂasks at 1.5×105 cells/ﬂask in culture medium in the presence or absence of 1 μMd m P G E 2. After culture for 3 days, the cells were collected and counted. Values are
the means+ −S.E.M. Similar results were obtained in three independent cell lines of mPGES-1-KD and control cells.
RESULTS
Reduced tumorigenic potential of mPGES-1-silenced LLC cells
in vitro
We established mPGES-1-KD LLC cells by means of an siRNA-
silencing strategy, as described in the Experimental section. The
expression levels of mPGES-1 and other enzymes involved in
PGE2 synthesis in mPGES-1-KD and mock cells were examined
by Western blot analysis (Figure 1A). The expression level
of mPGES-1 was reduced by ∼80% in mPGES-1-KD cells
relative to mock cells, whereas those of COX-1 and -2 and
other PGE synthases (cPGES and mPGES-2) in both cell lines
were approximately the same (Figure 1A, left-hand panel).
Furthermore, we found that, among the four EP receptor subtypes
that can bind to PGE2 [24], LLC cells expressed detectable levels
of EP2, EP3 and EP4 proteins, among which the level of EP2
protein was reduced in mPGES-1-KD cells relative to mock cells,
whereas the levels of EP3 and EP4 were unaffected by mPGES-1
silencing (Figure 1A, left-hand panel). The reduction in EP2, but
not EP4, expression in the KD cells was veriﬁed by quantitative
RT–PCR (Figure 1A, right-hand panel) and quantifying
individualimmunoblotsbyadensitometer(SupplementaryFigure
S1 at http://www.BiochemJ.org/bj/425/bj4250361add.htm). The
amounts of PGE2 released into the medium during culture
were decreased in mPGES-1-KD cells relative to mock cells
(Figure 1B), whereas those of 6-keto PGF1α (a non-enzymatic
hydrolytic product of PGI2)a n dP G F 2α were comparable between
mPGES-1-KD cells and mock cells (Figure 1C).
Concurrently, mPGES-1-KD cells grew more slowly than did
mock cells (Figure 1D). NS-398, a COX-2-selective inhibitor,
suppressed PGE2 generation and cell proliferation in mock cells
by∼60%and∼25%respectively,whereasnofurtherdecreases
in PGE2 production and cell growth were found in mPGES-1-KD
cells (Figures 1B and 1D). Production of 6-keto PGF1α and PGF2α
was equally sensitive to NS-398 in both cell lines (Figure 1C).
Furthermore, cell growth of mPGES-1-KD cells was partially
(even if not completely, probably because EP2 expression was
reduced in the KD cells; see above) restored by addition of an
optimal concentration (1 μM) of dmPGE2, a synthetic analogue
ofPGE2 (Figure1E).TheseresultssuggestthatthePGE2 produced
through the COX-2/mPGES-1 pathway is partially required for
the proliferation of LLC cells.
In the process of tumour metastasis, cancer cells from the
primary tumour must invade the ECM (extracellular matrix).
There are many reports demonstrating that malignant tumour
cells often possess high invasive activity [25]. Thus we next
assessed the effect of mPGES-1 silencing on the invasive activity
of LLC cells using Matrigel
TM invasion chambers. As shown in
Figure 2(A), the number of mPGES-1-KD cells migrating across
theMatrigel
TM-coatedﬁlterwasmarkedlyfewerthanthatofmock
cells. Since it is known that the PGE2 signalling activates the
invasive potential of cancer cells by increasing the expressions
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Figure 2 siRNA silencing of mPGES-1 in LLC cells reduces their malignant potential in vitro
(A) mPGES-1-KD and mock cells [1.2×106 cells in DMEM containing 3% (v/v) FCS] were seeded on to the upper wells of BD BioCoatTM MatrigelTM Invasion Chambers. DMEM containing
10% (v/v) FCS was added as a source of chemoattractants into the bottom wells of the plates. After 16h of incubation, cells that had invaded on to the lower surface of the chambers were ﬁxed,
stained with Crystal Violet and counted (left-hand panel). Values are the means+ −S.E.M. of ﬁve independent experiments. Representative photographs of mPGES-1-KD and mock cells that invaded
across the MatrigelTM-coated inserts are shown (right-hand panel). (B) The expression of VEGF protein in mPGES-1-KD and mock cells was assessed by immunoblotting (upper panel). The cell
lysates (20μg of protein equivalents) were separated by SDS/PAGE and then subjected to Western blot analysis using anti-VEGF and anti-α-tubulin antibodies. The activities of MMP-2 and -9 in
mPGES-1-KD andmockcells wereassessed bygelatin zymography(lowerpanel).Lysatesofcells (27 μgof proteinequivalents) weresubjected to SDS/PAGEcontaining1 mg/mlgelatin. Following
electrophoresis, the gels were incubated in a bath containing 1 μM ZnCl2 at 37◦C for 18h. The gels were then stained with 0.1% Coomassie Blue. The expression levels of mRNAs for VEGF,
MMP-2 and MMP-9 were evaluated by quantitative RT–PCR, with GAPDH mRNA used for normalization (means+ −S.D.; n=3) (right-hand panel). (C) Adhesion of mPGES-1-KD and mock cells
to ECM proteins. mPGES-1-KD or mock cells (2×105 cells) were seeded on to 35-mm dishes coated with collagen, ﬁbronectin or laminin in culture medium in the presence or absence of 1 μM
dmPGE2. After allowing cells to attach for 60min at 37◦C, non-adherent cells were removed by washing. Adherent cells were ﬁxed and stained with Giemsa solution and counted in three ﬁelds at
×40 magniﬁcation using a microscope and J image software. Values are the means+ − S.E.M. of ﬁve independent experiments. (D) Expression of α5a n dβ1 integrins in mPGES-1-KD and mock
cells. Total RNA was isolated from mPGES-1-KD and mock cells and subjected to quantitative RT–PCR using speciﬁc primers of α5 (left-hand panel) and β1 (right-hand panel) integrins and those
of GAPDH as a reference. The results of quantitative RT–PCR were normalized with their expression in mock cells being regarded as 1 (means+ −S.D., n=3). Similar results were obtained in two
independent cell lines of mPGES-1-KD and control cells.
of VEGF, a pro-angiogenic factor, and MMPs, which hydrolyse
type IV collagen localized in the basement membrane [25], we
nextexaminedtheeffectsofmPGES-1silencingontheexpression
of VEGF and the activities of MMP-2 and -9 by Western blot
analysis,gelatinzymographyandquantitativeRT–PCR.Asshown
in Figure 2(B), the activities of MMP-2 and -9 in the conditioned
medium from mPGES-1-KD cells were lower than those in
the medium from mock cells. Consistently, expression levels
of both MMP-2 and -9 mRNAs were signiﬁcantly reduced in
the KD cells relative to control cells. In contrast, the levels of
VEGFproteinandmRNAwereunaffectedbymPGES-1silencing
(Figure 2B). These results suggest that the silencing of mPGES-1
diminishes in vitro migration of LLC cells by reducing the PGE2-
induced expression of MMP-2 and -9.
TheabilityofcancercellstoadheretotheECMinﬂuencestheir
motility and invasion in tumour tissues in vivo, and metastatic
tumour cells show decreased ECM-adherent activity in vitro
[25,26]. Therefore we next studied the attachment of mPGES-1-
KD or mock cells to culture dishes pre-coated with distinct ECM
components. The results showed that the numbers of mPGES-1-
KD cells adhering to collagen and ﬁbronectin, but not to laminin,
weresigniﬁcantlyincreasedascomparedwiththoseofmockcells
(Figure 2C). Moreover, the increased adhesion of mPGES-1-KD
cells to collagen was reversed by dmPGE2 to the level of mock
cells, and adhesion of the cells to ﬁbronection also showed a
similar trend (Figure 2C). Consistent with the increased binding
of mPGES-1-KD cells to collagen and ﬁbronectin, the expres-
sions of their receptor components, α5a n dβ1 integrins, were
elevated in the KD cells relative to control cells (Figure 2D).
Thus we conclude that mPGES-1 supplies a majority of the PGE2
that enhances the malignant potential (in terms of ECM invasion
and adherence) of cancer cells.
Increased tumorigenic potential of mPGES-1-overexpressing LLC
cells in vitro
We next established LLC cells that stably overexpressed
mPGES-1 and examined whether these cells (as opposed to
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Figure 3 Increased PGE2 generation, proliferation and invasion of mPGES-
1-overexpressing LLC cells
(A) Expression of COX-2 and mPGES-1 in mPGES-1-overexpressing and mock cells was
assessed by Western blot analysis. Representative results of at least three experiments are
shown. (B and C) Effects of mPGES-1 overexpression on PGE2 generation (B) and cell growth
(C). mPGES-1-overexpressing and mock cells were seeded at 6×104 cells/well in six-well
culturedishes.Afterculturefor2days,thecellswerecollectedandcounted,andthesupernatants
weretakenforaPGE2 enzymeimmunoassay.Valuesarethemeans+ −S.E.M.ofﬁveindependent
experiments. (D) mPGES-1-overexpressing and mock cells (1.2×106 cells in the presence or
absenceof10nMNS-398)thathadinvadedthroughBDBioCoatTMMatrigelTMInvasionChamber
insertsover16hwerecounted.Valuesarethemeans+ −S.E.M.ofﬁveindependentexperiments.
Similar results were obtained in two independent cell lines of mPGES-1-overexpressing and
mock cells.
mPGES-1-KD cells) would show increased proliferation and
invasion. mPGES-1-transfected LLC cells expressed more
mPGES-1 protein than did mock cells, whereas the expression of
COX-2 protein was unaltered (Figure 3A). PGE2 release into the
medium during culture was increased by ∼2-fold in mPGES-1-
overexpressing cells relative to mock cells (Figure 3B). As shown
in Figure 3(C), the growth rate of mPGES-1-overexpressing cells
was signiﬁcantly faster than that of mock cells. Moreover, the
Matrigel
TM invasion chamber assay revealed that the invasive
activity of mPGES-1-overexpressing cells was notably higher
than that of mock cells (Figure 3D). Additionally, treatment of
both mock and mPGES-1-overexpressing LLC cells with NS-
398 reduced the invasion by ∼40% (Figure 3D). These results
conﬁrm that the increased production of PGE2 through the COX-
2/mPGES-1 pathway in cancer cells facilitates their proliferation
and invasion.
Silencing of mPGES-1 in cancer cells reduces tumorigenesis
in vivo
To assess the contribution of mPGES-1 in cancer cells to tumour
development in vivo, we grafted mPGES-1-KD and mock LLC
cells subcutaneously into BALB/c mice, and the development of
the solid tumour around the injection sites was evaluated on day
14 after implantation. Remarkably, both the volume and mass of
xenografts derived from mPGES-1-KD cells were signiﬁcantly
smaller than those derived from mock cells (Figures 4A and 4B).
The levels of prostanoids (PGE2,P G F 2α and 6-keto-PGF1α) in the
homogenates of xenografts did not differ signiﬁcantly between
the genotypes, even though PGE2 tended to decrease in the
xenografts from mPGES-1-KD cells compared with those from
mock cells (Figure 4C). The expression of VEGF, as assessed by
RT–PCR and quantitative RT–PCR, was reduced in mPGES-1-
KD xenografts as compared with control xenografts (Figure 4D).
Considering that VEGF expression was unaltered by silencing
of mPGES-1 in LLC cells in vitro (Figure 2B), the reduction
of VEGF expression in mPGES-KD xenografts in vivo may
reﬂect the action of mPGES-1-derived PGE2 from cancer cells
on proximal stromal cells in tumour microenvironments.
Reduced tumour growth and angiogenesis in mPGES-1-KO mice
The observations described above indicate that cancer cell-
associated COX-2 and mPGES-1 co-operatively produce PGE2,
which accelerate multiple steps of malignant progression,
including cell proliferation, invasion and ECM adhesion. In terms
of the pathological circumstances, it has been reported that COX-
2 and mPGES-1 are expressed not only in tumour cells, but
also in the stromal cells (mainly in inﬁltrating macrophages)
surrounding them [14,21]. To investigate the contribution of
host-associated mPGES-1 to tumour growth, we next grafted
parental LLC cells subcutaneously into either mPGES-1-KO or
WT mice, and evaluated the development of solid tumour around
the injection sites. Although the absence of mPGES-1 in the host
mice inﬂuenced neither the engraftment rate nor the growth of
tumoursduringtheﬁrst5 daysafterimplantation,tumoursgrafted
into the mPGES-1-KO mice were signiﬁcantly smaller in size
than those grafted into the WT mice after day 6 and beyond
(Figure 5A). On day 14 after implantation, the tumour mass in
mPGES-1-KO mice was reduced to half of that in WT mice
(Figure 5B, left-hand panel). The levels of PGE2 in homogenates
of the dissected tumour tissues were nearly 50% less in mPGES-
1-KO mice than in WT mice, whereas those of PGF2α were
unaffected by the host mPGES-1 deﬁciency (Figure 5B, right-
hand panel).
Histological examination of the xenografts revealed that the
vascularization of tumour tissues was markedly reduced by
the lack of host mPGES-1 expression (Figure 5C, indicated by
arrowheads). The vascular density was approx. 60% lower in
tumours grafted in mPGES-1-KO mice than those grafted in WT
mice (Figure 5D, left-hand panel). The haemoglobin contents in
the tumour tissues, which appeared to be well correlated with
tumour neovascularization upon histological examination [30],
were also reduced in mPGES-1-KO mice in comparison with
that in WT mice (Figure 5D, right-hand panel). The reduction of
tumourangiogenesisinmPGES-1-KOmicecausedalargeareaof
central necrosis in the xenografts of mPGES-1-KO, but not WT,
mice (Figure 5C, indicated by an asterisk). We further found that
the expression levels of the VEGF protein and mRNA in tumour
tissues were also markedly lower in mPGES-1-KO mice than in
WT mice (Figure 5E, left-hand panel). The decrease in VEGF
protein in the xenografts of mPGES-1-KO mice was conﬁrmed
by quantiﬁcation of the relative abundance of VEGF to α-tubu-
lin using a densitometer (Figure 5E, right-hand panel). These
results suggest that host mPGES-1-derived PGE2 plays a pivotal
role in tumour-associated VEGF production and accompanying
angiogenesis. Again, considering that VEGF expression was
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Figure 4 siRNA silencing of mPGES-1 in cancer cells reduces tumorigenesis in vivo
(A–C) mPGES-1-KD or mock cells (106 cells) were injected into the subcutaneous tissue of female BALB/c mice. On day 14 after implantation, tumour volume was scored according to the formula
V =(L ×W2)×0.5(A,left-handpanel).Thetumourtissueswerephotographedat ×100magniﬁcation(B),dissectedandweighed(A,right-handpanel).Valuesaremeans+ − S.E.M.(n=9).(C)
Amounts of PGE2,P G F 2α and 6-keto PGF1α in homogenates of the tumour tissues were quantiﬁed by enzyme immunoassay (means+ −S.E.M., n=9). (D) Expression of VEGF in tumour xenografts
of mPGES-1-KD and mock cells was assessed by RT–PCR followed by electrophoresis (left-hand panel) and quantitative RT–PCR (right-hand panel), with the expression of GAPDH as a reference
(means+ −S.D., n=4).
unaltered in mPGES-1-KD cells in vitro (Figure 2B), the reduced
expression of this angiogenic factor in tumour tissue in mPGES-
1-KO mice may reﬂect the impact of mPGES-1-derived PGE2
on tumour microenvironments rather than on tumour cells
in vivo.
We further examined the role of host-associated mPGES-1 in
tumour metastasis by intravenous injection of parental LLC cells
into mPGES-1-KO and WT mice. After 14 days, macroscopic
metastases, as assessed by Bouin’s staining, were found in the
lungs of both genotypes, but the number and size of metastatic
foci (Figure 6A) and the mass (Figure 6B, left-hand panel) of the
lungsweresigniﬁcantlyreducedinmPGES-1-KOmicecompared
with WT mice. Levels of PGE2 were reduced by nearly 50% in
homogenates of the lungs from mPGES-1-KO mice relative to
WT mice (Figure 6B, right-hand panel). Moreover, as assessed
by RT–PCR and quantitative RT–PCR, VEGF expression in the
metastasizedlungswassigniﬁcantlylowerinmPGES-1-KOmice
than in WT mice (Figures 6C and 6E). Gelatin zymography
revealed that the activity of MMP-2 in the metastasized lung
tissues was mitigated in mPGES-1-KO mice in comparison with
that in WT mice (Figure 6D), and the levels of both MMP-2
and -9 mRNAs were signiﬁcantly lower in the lung of mPGES-
1-KD mice than in that of WT mice (Figure 6E). Collectively,
these results indicate that host mPGES-1-driven PGE2 plays a
roleinpromotingtumourdevelopmentandmetastasis,whichwas
associated with increased VEGF expression and MMP-2 and -9
activation.
DISCUSSION
Although the concept that the PGE2 produced through the
COX-2-dependent pathway participates in the pathogenesis of
several types of cancer has been well established in the past
decade based on a series of genetic studies employing mice
ablated for the biosynthetic enzymes (COX-2) and receptors
(EPs) or pharmacological studies employing inhibitors or
agonists/antagonists fairly speciﬁc for them, the contribution of
a step between COX-2 and EPs, namely PGES enzymes that
convertCOX-2-producedPGH2 intoPGE2,tocancerdevelopment
has remained incompletely understood. In this context, we
have previously shown that co-transfection of mPGES-1 in
combinationwithCOX-2intoHEK-293cellsleadstoamalignant
phenotype [14]. In our continuing efforts to gain further insights
into the role of mPGES-1 in tumorigenesis, we used two
approaches in the present study. First, we performed siRNA-
mediated silencing and overexpression of mPGES-1, which
enabled us to address the complementary effects of endogenous
compared with overexpressed mPGES-1 in cancer cells on
tumorigenic potentials (growth, invasion and ECM binding in
vitro and tumour xenograft propagation in vivo). Secondly,
implantation of carcinoma cells into mPGES-1-KO mice and
WT mice allowed us to evaluate the contribution of mPGES-1
expressed in tissue microenvironments to the development and
metastasis of tumours in proximal and distant tissues. Our results
clearly indicate that mPGES-1 expressed in both cancer cells and
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Figure 5 Growth of LLC cells subcutaneously implanted into mPGES-1-KO and WT mice
A total of 105 cells were injected into the subcutaneous tissue of female mPGES-1-KO and WT mice. (A) Tumour volumes were scored on the indicated days as described in the Experimental
section. (B) On day 14 after implantation, the tumour tissues were dissected and weighed (left-hand panel). Amounts of PGE2 and PGF2α in homogenates of the tumour tissues were quantiﬁed by
enzyme immunoassay (right-hand panel). Results are presented as the means+ −S.E.M. (n=9). (C) Tumour tissues were cut out, ﬁxed in formalin, and stained with silver, haematoxylin and eosin
for histochemical analysis. Microvessels and necrotic regions are shown by arrowheads and an asterisk respectively. (D) Vascular density (left-hand panel) and haemoglobin content (right-hand
panel) were determined as described in the Experimental section. Results are presented as the means+ −S.E.M. (n=9). HPF, high-power ﬁeld. (E) Expression levels of VEGF protein (upper panel)
and mRNA (lower panel) in the tumour tissues were determined by Western blot and RT–PCR analysis respectively. Representative results of six independentexperiments are shown. On Western blot
analysis, the expression level of VEGF protein was quantiﬁed by a densitometer, with the expression level of α-tubulin used for normalization (means+ −S.D., n=6) (right-hand panel).
hosts is capable of promoting proliferation and invasion of cancer
cells in vitro and in vivo.
Role of mPGES-1 in cancer cells
We found that PGE2 generation and cell proliferation were
reduced by mPGES-1 knockdown (Figures 1A, 1B and 1D) and
conversely enhanced by mPGES-1 overexpression (Figures 3A–
3C) in LLC cells (a PGE2-dependent mouse lung carcinoma cell
line; [27]), indicating the role of mPGES-1, acting downstream
of COX-2, in providing the mitogenic PGE2. In accordance with
the impact on cell proliferation, the gene silencing of mPGES-1
decreased, whereas overexpression of mPGES-1 increased, the
invasive activity of LLC cells (Figures 2A and 3D). The process
by which tumour cells break out from their site of origin and
metastasize to distant sites requires an ability to invade through
the ECM and underlying mesenchymal cells. PGE2 stimulates
the invasion of cancer cells through up-regulating MMP-2 and
MMP-9 (type IV collagenases), as shown by the observations
that MMP-2 is increased in COX-2-overexpressing or PGE2-
treated tumour cells [25,26,28,29], and that MMP-9 is induced
by COX-2/EP4 signalling in macrophages [30]. We found that
the expression of MMP-2 and -9 in mPGES-1-KD cells were
lower than that in mock cells (Figure 2B), suggesting the con-
tribution of these matrix-degrading proteases to the mPGES-1-
dependent invasiveness of LLC cells. In addition to adhesion to
anddegradationoftheECM,detachmentfromtheECMisalsoan
importantstepinthemetastasisoftumourcells[25,26].Asshown
in Figure 2(C), both collagen- and ﬁbronectin-adherent activities
weresigniﬁcantlyincreasedinmPGES-1-KDcells,andtreatment
with dmPGE2 reversed these activities consistently. Accordingly,
the expression of integrin α5β1 (a major adhesion molecule
of ﬁbronectin) in mPGES-1-KD cells was higher than that in
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Figure 6 Reduced lung metastasis in mPGES-1-KO mice
A total of 105 cells were injected into the lateral tail veins of female mPGES-1-KO and WT mice on the BALB/c background. On day 14 after implantation, the mice were killed, and the removed
lungs were weighed (B, left-hand panel) and then stained with Bouin’s solution (A). Amounts of PGE2 in homogenates of the metastasized lung tissues were measured by enzyme immunoassay
(B, right-hand panel). (C) Expression of VEGF and GAPDH mRNAs were assessed by RT–PCR. (D) Activities of MMP-2 and -9 were evaluated by gelatin zymography. Results are presented as the
means+ −S.E.M. (n=4) in (B) and representative results of four independent experiments are shown in (A, C and D). (E) The expression levels of mRNAs for VEGF, MMP-2 and MMP-9 were
evaluated by quantitative RT–PCR, with GAPDH mRNA used for normalization (means+ −S.D., n=4).
mock cells (Figure 2D), an observation that is reminiscent of our
previous report that co-overexpression of COX-2 and mPGES-1
in HEK-293 cells results in a marked reduction in a subset of
integrins [14]. Thus mPGES-1-driven PGE2 may regulate the
ECM-adherent activity of cancer cells by altering the expression
of integrins.
Importantly, in vivo tumour growth after subcutaneous
engraftment of mPGES-1-KD cells was less obvious than that
after engraftment of replicate mock cells (Figure 4), implying
that mPGES-1 contributes to the supply of the major pool of
the PGE2 mediating tumour proliferation both in vitro and in
vivo. Gene disruption of EP2 resulted in a reduced number and
size of intestinal polyps in Apc-mutant mice, a model for human
familial adenomatous polyposis [31], and the Apc mutation is
accompaniedbyaberrantactivationofβ-cateninsignalling,which
is accelerated by PGE2 through the EP2–Gsα axis [32,33]. In
another model, disruption of the gene for EP1, EP2 or EP4
suppressed the development of colorectal cancer induced by
carcinogens [34–36]. Transactivation of EGF (epidermal growth
factor) receptors by the PGE2/EP1, 2, or 4 signalling via protein
kinase A and c-Src led to increased cell growth and invasion of
carcinoma cells [37–39]. In a positive-feedback loop, COX-2-
derived PGE2 acts on EP2,leading to the elevation of intracellular
cAMP, which in turn up-regulates the expressions of both COX-2
and EP2 [40]. Although the identiﬁcation of EPs participating
in the propagation of LLC xenografts is beyond the scope of
the present study, the co-ordinated reduction of mPGES-1 and
EP2 in mPGES-1-KD cells (Figure 1A) suggests that COX-
2/mPGES-1-derived PGE2 may stimulate EP2 signalling in an
autocrine/paracrine fashion to facilitate LLC cell proliferation
and, accordingly, defects in mPGES-1 may lead to down-
regulation of EP2 and eventually reduce the cellular sensitivity
to PGE2.
While this paper was in preparation, two groups
reported opposite effects of mPGES-1 deﬁciency in intestinal
tumorigenesis. Nakanishi et al. [41] showed that the genetic
deletion of mPGES-1 ameliorates the development of intestinal
tumours in both Apc
Δ14-dependent and carcinogen-induced
models, whereas Elander et al. [42] demonstrated that intestinal
polyposis is exacerbated in mPGES-1-null Apc
min mutant mice,
probably because of the metabolic shift from PGE2 towards
other pro-tumorigenic lipid mediators. Although the reason
for the discrepancy between these two studies is unclear, our
present results appear to be in line with the former study and
thus support the feasibility of targeting mPGES-1 for cancer
chemoprevention. Critically, although the experimental design
of the previous studies did not allow a precise distinction between
the contribution of cancer cell- and host-associated mPGES-1 to
tumour development, our present approach clearly underscores
the importance of mPGES-1 pools both in cancer cells (as
discussed above) and in microenvironments (see below).
Role of mPGES-1 in host microenvironments
As is COX-2, mPGES-1 is expressed in stromal cells as well
as in cancerous cells in several types of tumour [14,15]. Given
that stromal COX-2 and PGE2 of the host can inﬂuence the
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development of grafted tumours [20,43], we used mPGES-1-KO
mice to evaluate the potential roles of the host stromal mPGES-1
in tumour growth, and found that tumour growth at a proximal
site and metastasis into a distant tissue were signiﬁcantly reduced
in mPGES-1-KO mice relative to WT mice (Figures 5 and 6).
This result provides an additional line of genetic evidence that
the COX-2/mPGES-1-derived PGE2 from host stromal cells, in
addition to that from cancer cells (see above), is important for
tumorigenesis in vivo. The induction of mPGES-1 in tumour
stromal tissues may be ascribed to the migration and expansion of
host inﬂammatory cells and neovascular endothelial cells, since
previous immunohistochemical analyses have demonstrated a
preferential localization of mPGES-1 in macrophage-like cells
inﬁltrating into the stromal tissues in proximity to cancer
cells [14], and since massive macrophage inﬁltration and
microvesselformationhavebeenobservedinthestromaofgastric
hyperplasiain COX-2/mPGES-1-double transgenicmice[16,17].
As shown in Figure 5, vascular density and VEGF expression
in tumour xenografts were decreased in mPGES-1-KO mice. It
hasbeenreportedthatangiogenesisinducedbyeitherendogenous
COX-2orexogenousPGE2 wasaccompaniedbyincreasedVEGF
expression and was abolished by a VEGF-directed antisense
oligonucleotide [19]. Moreover, the growth, VEGF expression
and angiogenesis of LLC-implanted tumours were markedly
suppressed in EP3-KO mice [43], a phenotype that is reminiscent
of mPGES-1-KO (the present study) and COX-2-KO mice [20].
These studies indicate that, in the tumour milieu, both cancer
cells and adjacent stromal cells synthesize (via COX-2/mPGES-
1) PGE2, which in turn acts on the particular population of EP3-
expressing stromal cells to induce the production of VEGF and
consequent angiogenesis [43]. Consistently, Nakanishi et al. [41]
have reported very recently that genetic deletion of mPGES-1
in Apc-mutant mice caused marked and persistent suppression
of intestinal cancer growth in association with a disorganized
vascular pattern. In addition to tumour growth and associated
angiogenesis, lung metastasis of LLC cells across the blood
circulationwasalsodecreasedinmPGES-1-KOmiceascompared
with replicate WT mice (Figure 6). The metastatic phenotype
observed in mPGES-1-KO mice was similar to that observed
in MMP-2-KO mice, in which focal xenograft propagation and
lung metastasis of LLC cells were reduced [44]. In agreement,
MMP-2, as well as MMP-9, expression in the metastasized lung
tissues was markedly lower in mPGES-1-KO mice than in WT
mice (Figures 6D and 6E). Thus, in the metastatic foci, the PGE2
derived from the host mPGES-1 may lead to the increase in the
activities of MMP-2 and -9, which, in co-operation with VEGF,
may promote the invasion of cancerous cells into the adjacent
and distant tissues, thereby allowing subsequent expansion and
metastasis of the tumour.
In conclusion, the results of the present study suggest that
both cancer cell-associated and host-derived mPGES-1 is critical
for tumour growth and metastasis. The mPGES-1-driven PGE2
signalling on stromal cells may be functionally linked to
the induction of potent pro-angiogenic and matrix-degrading
factors, which in turn would facilitate tumour development.
Previous studies have shown that, unlike the speciﬁc inhibition
of COX-2, which predisposes to cardiovascular risk, gene
ablation of mPGES-1 in mice shows minimal unfavourable
effects on the circulation system [12]. Therefore an mPGES-1
inhibitor would exhibit a chemopreventive action on various
tumours by attenuating both cancer cell- and stromal cell-
derived PGE2, thereby serving as a novel therapeutic tool for
cancer. Future clinical studies will address the important question
of the efﬁcacy and safety of mPGES-1 inhibition in human
diseases.
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Figure S1 Reduced expression level of EP2 protein in mPGES-1-silenced
LLC cells in vitro
Expression of EP2 and EP4 in mPGES-1-KD and control (mock) cells was assessed by
immunoblotting. Representative results of at least three experiments are shown. On Western
blot analysis the expression levels of EP2 and EP4 protein were quantiﬁed by a densitometer,
with the expression level of α-tubulin used for normalization (means+ −S.D., n=3).
Received 8 January 2009/8 October 2009; accepted 21 October 2009
Published as BJ Immediate Publication 21 October 2009, doi:10.1042/BJ20090045
1 To whom correspondence should be addressed (email haras@pharm.showa-u.ac.jp).
2 Professor Kudo died on April 27, 2008. We greatly miss him as a scientist and a friend. We offer sincere thanks to all the friends, colleagues and
former collaborators of Professor Kudo who showed him kindness during his lifetime.
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.